Jiang 2015b.

Methods	Study design: Randomised clinical trial Study duration: Not reported Duration of follow‐up: 2 years Setting: Hospital
Participants	Age (mean ± SD, range): TACE + RFA: 63.65 ± 9.31 years, 41‐82 years; TACE alone: 62.18 ± 9.07 years, 43‐79 years Male (n/total): TACE + RFA: 17/30; TACE alone: 16/30 Tumour diameter (mean ± SD, range): TACE + RFA: 5.07 ± 1.13 cm, 3‐10.5 cm, TACE: 5.12 ± 1.04 cm, 2.8‐10.6 cm TNM stage (patients): Stage Ⅰ: TACE + RFA: 10; TACE: 9 Stage Ⅱ: TACE + RFA: 12; TACE: 14 Stage Ⅲ: TACE + RFA: 7; TACE: 7 Child‐Pugh Class (patients): Class A: TACE + RFA: 25; TACE alone: 23 Class B: TACE + RFA: 5; TACE alone: 7
Interventions	TACE + RFA group (n = 30): TACE: Chemotherapeutic drugs: oxaliplatin 100‐150 mg and theprubicin 40‐60 mg. Two sessions of TACE were performed, with an interval of one month. RFA: The interval between TACE and RFA was 2 weeks. RANDIONICS system. Output power of 0‐200 W and frequency of 480 kHz TACE group (n = 30): Chemotherapeutic drugs: oxaliplatin 100‐150 mg and theprubicin 40‐60 mg. Two sessions of TACE were performed, with an interval of one month.
Outcomes	Tumour response: measured by contrast‐enhanced CT at 1 month after treatment 1‐ and 2‐year survival rates Progression‐free survival
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.